The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Immune Cell Engineering For Targeted Therapy And Disease Monitoring in Type 1 Diabetes (R01 Clinical Trial Not Allowed)
This initiative will support the engineering of immune cells to target the human pancreatic compartment to report on previously inaccessible information about diabetes initiation and progression, and/or to deliver environment-specific therapeutic responses to restore islet health and prevent the progression to T1D.
Letter of Intent Due Date(s): May 22, 2021
Application Due Date(s): June 22, 2021
RFA-DK-21-005 Expiration Date June 23, 2021
Application budgets are limited to $600,000 direct costs per year. The budget needs to reflect the scientific scope of the proposed project.
The maximum project period is 5 years.